目的 探讨艾托格列净联合沙格列汀治疗2型糖尿病的临床疗效。方法 选取2023年1月—2024年7月成都市龙泉驿区中医医院收治的100例2型糖尿病患者，按照随机数字法分为对照组和治疗组，每组各50例。对照组患者给予口服沙格列汀片，5 mg/次，1次/d。治疗组在对照组的基础上口服艾托格列净片，5 mg/次，1次/d。两组治疗12周观察效果。观察两组临床疗效，比较两组餐后2 h血糖（2 hPBG）、空腹血糖（FPG）、糖化血红蛋白（HbA1c）、简明健康状况调查量表（SF-36）评分、胰岛素抵抗指数（HOMA-IR）、网膜素-1（Omentin-1）、胰升血糖素样肽-1（GLP-1）、白细胞介素-1β（IL-1β）、成纤维细胞生长因子-21（FGF-21）水平。结果 治疗12周后，治疗组总有效率是96.00%，显著高于对照组总有效率82.00%（P＜0.05）。治疗后，两组2 hPBG、FPG、HbA1c水平均较治疗前显著降低（P＜0.05）；治疗后，与对照组对比，治疗组患者2 hPBG、FPG、HbA1c指标均更低（P＜0.05）。治疗后，两组HOMA-IR显著降低，SF-36评分升高（P＜0.05）；治疗后，与对照组对比，治疗组的HOMA-IR降低，且SF-36评分升高（P＜0.05）。治疗后，两组Omentin-1、GLP-1水平较同组治疗前显著升高，而IL-1β、FGF-21水平显著降低（P＜0.05）；治疗后，治疗组Omentin-1、GLP-1水平高于对照组，IL-1β、FGF-21水平低于对照组（P＜0.05）。结论 艾托格列净联合沙格列汀治疗2型糖尿病具有显著的临床疗效，可以较好的降低血糖相关指标，提高患者生活质量水平，调节炎症反应，具有临床应用价值。

Objective To explore the clinical study of etoglitazone combined with shagliptin in treatment of type 2 diabetes. Methods 100 Patients with type 2 diabetes admitted to Longquanyi District Traditional Chinese Medicine Hospital of Chengdu from January 2023 to July 2024 were selected and divided into control group and treatment group according to the random number method, with 50 cases in each group. Patients in the control group were given oral Saxagliptin Tablets, 5 mg each time, once daily. Patients in the treatment group orally took Etogliflozin Tablets, 5 mg each time, once daily on the basis of control group. The effects of two groups were observed after 12 weeks of treatment. The level of 2 hPBG, FPG, HbA1c, SF-36 score, HOMA-IR, Omentin-1, GLP-1, IL-1β, FGF-21 in two groups were compared. Results After 12 weeks of treatment, the total effective rate of treatment group was 96.00%, significantly higher than 82.00% of control group (P < 0.05). After treatment, the levels of 2 hPBG, FPG, and HbA1c in both groups were significantly lower than those before treatment (P < 0.05). After treatment, compared with the control group, 2 hPBG, FPG, and HbA1c in the treatment group were all lower (P < 0.05). After treatment, HOMA-IR in both groups decreased significantly, but the SF-36 score increased (P < 0.05). After treatment, compared with the control group, the HOMA-IR of the treatment group decreased, and the SF-36 score increased (P < 0.05). After treatment, the levels of Omentin-1 and GLP-1 in both groups were significantly increased compared with those before treatment in the same group, but the levels of IL-1β and FGF-21 were significantly decreased (P < 0.05). After treatment, the levels of Omentin-1 and GLP-1 in the treatment group were higher than those in the control group, and the levels of IL-1β and FGF-21 were lower than those in the control group (P < 0.05). Conclusion Etogliflozin combined with saxagliptin has a significant clinical efficacy in the treatment of type 2 diabetes, and can effectively lower blood sugar-related indicators, improve the life quality of patients, and regulate inflammatory responses, which has clinical application value.

R977

成都市医学科研课题立项项目（2023273）